Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07361276

Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Florianópolis, Brazil

Location status: Recruiting

About this study

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

The retrospective cohort design allows for efficient use of existing clinical data to evaluate real-world practice against national guideline recommendations. The primary outcomes relate to treatment decisions and delays rather than interventional effects; therefore, an observational design is methodologically appropriate and ethically preferable.

The study will be conducted across 05 Brazilian municipalities participating in the epHealth Primary Care Solutions platform. These municipalities span multiple regions and reflect heterogeneity in socio-demographic context, healthcare infrastructure, and epidemiological profiles.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years at the time of Hypertension diagnosis
  • Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period.
  • Continuous follow-up in the same municipality for at least 6 months after index measurement.
  • Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions

Exclusion criteria

  • Patients with incomplete data or not traceable in the registration systems

Treatment and study plan

Primary outcomes

  1. Uncontrolled blood pressure

    Time frame: through study completion, an average of 1 year

    Proportion of patients with uncontrolled blood pressure (BP ≥ 140/90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.

Secondary outcomes

  1. Antihypertensive treatment

    Time frame: through study completion, an average of 1 year

    Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.

  2. Risk stratification

    Time frame: through study completion, an average of 1 year

    Likelihood of treatment escalation stratified by low/moderate vs. high/very high CV risk.

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Clinical Landscape of Epidemiology and Assessment of Results in Hypertension

Acronym: CLEAR-HTN

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 23, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.